[1]朱 晶,王琦苑,钱 蓉,等.消痰散结方联合卡培他滨治疗晚期胃癌临床研究[J].陕西中医,2024,(2):191-195.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.009]
　ZHU Jing,WANG Qiyuan,QIAN Rong,et al.Clinical study on the treatment of advanced gastric cancer with Xiaotan Sanjie formula combined with capecitabine[J].,2024,(2):191-195.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.009]
点击复制

消痰散结方联合卡培他滨治疗晚期胃癌临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年2期
页码:
191-195
栏目:
临床研究
出版日期:
2024-02-05

文章信息/Info

Title:
Clinical study on the treatment of advanced gastric cancer with Xiaotan Sanjie formula combined with capecitabine
作者:
朱 晶; 王琦苑; 钱 蓉; 李成银
(湖北省中医院 湖北中医药大学附属医院 湖北省中医药研究院,湖北 武汉 430061)
Author(s):
ZHU Jing; WANG Qiyuan; QIAN Rong; LI Chengyin
(Hubei Provincial Hospital of Traditional Chinese Medicine,Wuhan 430061,China)
关键词:
胃癌;  消痰散结方;  卡培他滨;  化疗;  糖类抗原199;  血清基质金属蛋白酶3
Keywords:
Gastric cancer;  Xiaotan Sanjie formula;  Capecitabine;  Chemotherapy;  Carbohydrate antigen 199;  Matrix metalloproteinase-3
分类号:
R 256.3
DOI:
DOI:10.3969/j.issn.1000-7369.2024.02.009
文献标志码:
A
摘要:
目的:研究探讨消痰散结方联合卡培他滨维持化疗对晚期胃癌复发转移的影响。方法:选自晚期胃癌患者80例,随机抽取平均分两组,各有40例,对照组采取卡培他滨维持化疗,观察组采取消痰散结方联合卡培他滨维持化疗,观察比较两组治疗后1年内复发、转移及生存情况,并比较治疗前后血清肿瘤标志物、卡氏功能评分(KPS)、血清基质金属蛋白酶3(MMP-3)、基质金属蛋白酶9(MMP-9)、T淋巴细胞亚群的变化,观察化疗期间不良反应发生率。结果:观察组总复发转移率25.00%,明显低于对照组总复发转移率55.00%(P<0.05); 观察组1年生存率67.50%明显高于对照组1年生存率32.50%(P<0.05)。观察组治疗后血清肿瘤标志物、KPS评分、T淋巴细胞亚群均明显改善(P<0.05),MMP-3、MMP-9有所升高,但升高幅度明显小于对照组(P<0.05),组间比较均有统计学差异(P<0.05)。观察组的疾病控制率80.00%明显优于对照组50.00%(P<0.05); 观察组化疗期间总不良反应率10.00%明显低于对照组42.50%(P<0.05)。结论:晚期胃癌患者采用消痰散结方联合卡培他滨维持化疗,可有助调节机体免疫力,降低复发转移率,预防或减少治疗期间不良反应,提高生活质量。
Abstract:
Objective:To investigate the effect of Xiaotan Sanjie formula combined with capecitabine maintenance chemotherapy on the recurrence and metastasis of advanced gastric cancer.Methods:A total of 80 patients with advanced gastric cancer were randomly divided into two groups,with an average of 40 cases each group.The control group received maintenance chemotherapy with capecitabine,while the observation group received treatment with Xiaotan Sanjie formula combined with maintenance chemotherapy with capecitabine.The recurrence,metastasis,and survival status of the two groups within one year after treatment were observed and compared,and the serum tumor markers,KPS,before and after treatment were compared the changes in serum matrix metalloproteinase-3(MMP-3),matrix metalloproteinase-9(MMP-9),and T lymphocyte subsets were observed,and the incidence of adverse reactions during chemotherapy was observed.Results:The total recurrence and metastasis rate of 25.00% in the observation group was significantly lower than that of 55.00% in the control group(P<0.05),and the one-year survival rate of 67.50% in the observation group was significantly higher than that of 32.50% in the control group(P<0.05).After treatment,the serum tumor markers,KPS score,and T lymphocyte subpopulations in the observation group were significantly improved(P<0.05).MMP-3 and MMP-9 increased,but the increase was significantly smaller than that in the control group(P<0.05).There were statistical differences between the groups(P<0.05).The disease control rate of 80.00% in the observation group was significantly higher than that of 50.00% in the control group(P<0.05).The total adverse reaction rate of 10.00% during chemotherapy in the observation group was significantly lower than 42.50% in the control group(P<0.05).Conclusion:The combination of Xiaotan Sanjie formula and capecitabine maintenance chemotherapy for advanced gastric cancer patients can help regulate the body's immune system,reduce recurrence and metastasis rates,prevent or reduce adverse reactions during adverse periods,and improve quality of life.

参考文献/References:

[1] 颜倩英,温本,陈敏,等.卡培他滨维持化疗治疗晚期和术后复发转移胃癌效果观察[J].中国处方药,2020,18(11):74-75.
[2] 许瑶,许尤琪,沈明勤.健脾化痰方抗胃癌转移及对Survivin、Bax的影响[J].世界中西医结合杂志,2018,13(1):35-38,43.
[3] 蒋峰,柳小芳,高艺文,等.解毒散结方联合化疗治疗晚期胃癌疗效及对患者血管内皮生长因子和受体的影响[J].陕西中医,2021,42(5):582-585.
[4] 国家卫生健康委员会.胃癌诊疗规范(2018年版)[J].中华消化病与影像杂志,2019,9(3):118-144.
[5] 王德禄.中医内科学[M].北京:中国中医药出版社,2006:407-424.
[6] TERRET C,ALBRAND G,MONCENIX G,et al.Karnofsky Performance Scale(KPS)or Physical Performance Test(PPT)that is the question[J].Critical Reviews in Oncology/Hematology,2011,77(2):142-147.
[7] TROTTI A,COLEVAS A D,SETSER A,et al.CTCAE v3.0:Development of a comprehensive grading system for the adverse effects of cancer treatment[J].Semin Radiat Oncol,2003,13(3):176-181.
[8] EISENHAUER E A,THERASSE P,BOGAERTS J,et al.Newresponse evaluation criteria in solid tumours:Revised RECIST guide line(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[9] 严安.扶正解毒方对胃癌术后患者复发转移及生存质量的干预研究[D].北京:北京中医药大学,2018.
[10] 黄前堂,林武华,周琦,等.卡培他滨维持化疗在晚期或术后复发转移胃癌患者中的效果观察[J].癌症进展,2021,19(9):939-941.
[11] 谢之微,杨婉花,金润麟,等.替吉奥联合奥沙利铂治疗中晚期胃癌并发肝转移临床疗效及安全性研究[J].陕西医学杂志,2018,47(2):235-237.
[12] 宋成鑫,葛信国,储晶.养阴健脾散毒法辅助化疗治疗晚期胃癌临床研究[J].陕西中医,2020,41(11):1543-1547.
[13] 聂梦君.益气化瘀解毒方配合奥沙利铂联合氟尿嘧啶类化疗对胃癌术后复发转移风险影响的临床研究[D].南京:南京中医药大学,2022.
[14] 闵亮,祁宏,王海桥,等.痰瘀同治方联合化疗治疗进展期胃癌术后60例临床观察[J].中国中西医结合消化杂志,2017,25(7):481-484.
[15] 余志红,赵颖,魏品康,等.消痰散结方对原位移植胃癌裸鼠生长及血清IL-8、TGF-β的影响[J].中华中医药学刊,2018,36(10):2382-2385.
[16] 刘香来,刘继微,李海川,等.消痰散结方联合放疗对肺癌大鼠癌细胞凋亡、免疫功能及肿瘤标志物的影响[J].中国中医急症,2023,32(1):68-71,86.
[17] 杨丽,周易,王晓明,等.炮制对半夏化学成分及药理作用研究进展[J].辽宁中医药大学学报,2022,24(2):49-53.
[18] 黄维琳,梁枫,汪荣斌,等.天南星抗肿瘤作用研究进展[J].承德医学院学报,2017,34(3):221-223.
[19] 任小瑞,张恩欣,吴红洁.中药全蝎抗肿瘤的研究进展[J].中华中医药学刊,2021,39(11):90-93.
[20] 杨晓慧,李雁.中药蜈蚣抗肿瘤作用的研究进展[J].中成药,2017,39(2):373-377.
[21] 李向阳,任磊,梁瑞.血清基质金属蛋白酶-9、基质金属蛋白酶-2水平对胃癌腹膜转移及预后的预测价值[J].陕西医学杂志,2023,52(2):166-170.
[22] 许瑶.健脾化痰方治疗胃癌的临床疗效观察及抗转移的机理研究[D].南京:南京中医药大学,2017.
[23] 曹丽萍.消痰散结方通过调控LncRNA-ATB抑制胃癌细胞增殖和转移[D].杭州:浙江中医药大学,2023.
[24] 张映城.消痰散结方调控VEGF信号通路抑制胃癌淋巴转移的研究[D].上海:第二军医大学,2018.
[25] 赵颖,陆烨,施俊,等.消痰散结方为基础的中药辨证治疗对中晚期胃癌无进展生存期影响的研究[J].中国中西医结合消化杂志,2017,25(5):332-335,339.

相似文献/References:

[1]裴俊文,孙太振△,蒋立峰.基于对SGC7901细胞Survivin、Bcl2基因的调控 探讨益气化瘀散结方影响胃癌细胞增殖凋亡的作用机制*[J].陕西中医,2019,(4):411.
　PEI Junwen,SUN Taizhen,JIANG Lifeng..Study on the effect of Yiqi Huayu Sanjie decoction on the proliferation and apoptosis of gastric cancer cells based on the regulation of survivin and Bcl2 gene in SGC7901 cells[J].,2019,(2):411.
[2]高聪聪,范 筱,李 宁.益气健脾化积方对胃癌化疗疗效、患者安全性及预后影响的研究*[J].陕西中医,2019,(4):475.
[3]杨国强,闫强△.健脾解毒汤结合射频消融术治疗胃癌肝转移疗效研究[J].陕西中医,2019,(11):1510.
　YANG Guoqiang,YAN Qiang..Therapeutic effect of Jianpi Jiedu decoction combined with radiofrequency ablation on liver metastases from gastric cancer[J].,2019,(2):1510.
[4]马 婷,王品昊,朱 婕,等.行健汤联合穴位贴敷治疗进展期胃癌癌因性疲乏疗效及对患者免疫功能的影响*[J].陕西中医,2020,(10):1410.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.019]
[5]宋成鑫,葛信国△,储 晶.养阴健脾散毒法辅助化疗治疗晚期胃癌临床研究*[J].陕西中医,2020,(11):1543.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.007]
　SONG Chengxin,GE Xinguo,CHU Jing..Advanced gastric cancer treated by the method of nourishing Yin and invigorating spleen and dispersing toxin[J].,2020,(2):1543.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.007]
[6]周 锐,马灏川,陈亚栋,等.针灸辅助治疗胃癌现状及展望[J].陕西中医,2021,(8):1150.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.040]
　ZHOU Rui,MA Haochuan,CHEN Yadong,et al.Review of acupuncture and moxibusition on gastric cancer[J].,2021,(2):1150.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.040]
[7]孟 肖,张新庆,李 璐,等.培元益气汤改善气阴两虚证胃癌相关癌性疲乏及对患者免疫功能的影响[J].陕西中医,2023,(2):174.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.008]
　MENG Xiao,ZHANG Xinqing,LI Lu,et al.Peiyuan Yiqi decoction improves cancer-related fatigue of gastric cancer with deficiency of qi and yin and its effect on immune function[J].,2023,(2):174.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.008]
[8]苏园园,刘宁宁,赖优莹,等.胃癌中医证型研究进展[J].陕西中医,2023,(2):262.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.029]
　SU Yuanyuan,LIU Ningning,LAI Youying,et al.Progress in traditional Chinese medicine syndrome types research of gastric cancer[J].,2023,(2):262.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.029]
[9]李琳婵,鱼麦侠,郝梅梅,等.调中化湿汤对胃癌小鼠炎症损伤干预机制[J].陕西中医,2023,(3):294.[doi:DOI:10.3969/j.issn.1000-7369.2023.03.005]
[10]熊 婷,薛川松,颜 晔.益气养血汤联合参芪扶正注射液治疗胃癌患者肿瘤相关性贫血疗效研究[J].陕西中医,2023,(8):1065.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.015]
　XIONG Ting,XUE Chuansong,YAN Ye.Effect of Yiqi Yangxue decoction combined with Shenqi Fuzheng injection on cancer related anemia in patients with gastric cancer[J].,2023,(2):1065.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.015]

备注/Memo

备注/Memo:
基金项目:国家中医药管理局科研项目(2019XZZX-ZL002)
更新日期/Last Update: 2024-02-07